Clinical-stage Opportunity Focus on early-stage negotiation with CROs and academic partners involved in PTSD, opioid use disorder, and neuropsychiatric trials to explore collaborative development, co-funding, and access to Nantheia™ delivery technology.

Partnership Potential Leverage UCLA and University of Nebraska collaborations as proof points to engage major medical centers and research institutions for trial expansion, site activation, or investigator-initiated studies using Nantheia™ formulations.

Global IP Advantage Promote expanding market access through 35+ patent protections globally; target pharma players seeking CBD-based therapies with robust IP coverage and 2040+ expiration horizons for competitive moat and exclusive rights.

Therapeutic Demand Position Nantheia™ as a high-bioavailability CBD platform with potential for PTSD, social anxiety, opioid addiction, and smoking cessation programs; approach payers and health systems focusing on neuropsychiatric burden and non-opioid treatment alternatives.

Manufacturing Readiness Highlight GxP-compliant manufacturing and stable Liquid Structure™ delivery as a scalable differentiator to potential CDMOs, contract manufacturers, and pharma partners seeking reliable CBD formulations with consistent bioavailability for trials and commercialization.